Protecting newborns from respiratory syncytial virus (RSV) has moved from promise to proven practice, with Scotland's maternal vaccination program demonstrating remarkable real-world effectiveness just months after implementation. This population-level success offers crucial evidence for expectant mothers weighing vaccination decisions and health systems considering similar programs.
The Scottish study tracked all singleton births from August 2024 through March 2025, comparing RSV hospitalization rates between infants whose mothers received the bivalent RSVpreF vaccine during pregnancy versus those who did not. Among infants under 90 days old requiring hospital admission for RSV-related lower respiratory tract infections, maternal vaccination reduced severe disease risk by 71 percent. The protection was most pronounced in the youngest, most vulnerable infants—those under 60 days—where effectiveness reached 75 percent.
This real-world validation carries significant weight beyond the controlled clinical trial environment. Unlike pharmaceutical trials with carefully selected participants, this study captured the messy reality of population health: varying maternal health conditions, diverse socioeconomic backgrounds, and the full spectrum of infant vulnerability. The timing is particularly compelling, as RSV typically peaks during winter months when healthcare systems face maximum strain. Scotland's decision to offer vaccination from 28 weeks gestation appears strategically sound, allowing sufficient time for maternal antibody transfer while maintaining high effectiveness. For health policy, this represents confirmatory evidence that maternal RSV vaccination programs can deliver on their promise, potentially reshaping pediatric respiratory medicine and reducing the substantial burden RSV places on families and healthcare infrastructure during peak seasons.